A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

Фаза 3 Идёт, набор закрыт NCT01946204

Заболевание	Prostatic Neoplasms
Фаза	Фаза 3
Спонсор	Aragon Pharmaceuticals, Inc.
Статус	Идёт, набор закрыт
Участники	1,207 участн.
Вмешательство	Apalutamide
Дата начала	14.10.2013
Дата завершения	19.05.2017
Публикация результатов	19.06.2018

Кратко

The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.

Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR)

Up to approximately 43 Months · Months

Placebo	16.20 Months
Apalutamide	40.51 Months
Placebo	15.70 Months
Apalutamide	40.51 Months

p-value	<0.0001
Hazard Ratio (HR)	0.280 (95% CI 0.227–0.346)

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery — Wake Forest University Health Sciences
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced P — National Cancer Institute (NCI)
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castr — National Cancer Institute (NCI)
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abirate — Janssen Research & Development, LLC
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Ola — National Cancer Institute (NCI)
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Pr — Janssen Research & Development, LLC

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.

English 한국어 日本語中文 Русский